Fibrosis, Liver
44
12
20
11
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.3%
1 terminated out of 44 trials
91.7%
+5.2% vs benchmark
9%
4 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (44)
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Volatile Organic Compounds for the Assessment of Liver Disease
Liver Cancer Prevention Randomized Control Trial
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Endoscopic Ultrasound Shear Wave Elastography Study
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Screening for Chronic Liver Diseases in General Population
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Chronic Hepatitis B Virus Infection in Zambia
LITMUS Imaging Study
Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial
Stem Cell Applications in Biliary Atresia Patients
Find HDV and Determine Its Status in Turkey
Global Research Initiative for Patients Screening on MASH
Reducing Non-Alcoholic Steatohepatitis
HIBOC = Hepatic Imaging Biomarkers in Obese Children
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis